Oct 12, 2026 07:15AM
Oct 12, 2026 07:15AM
Sep 25, 2026 04:30PM
Sep 9, 2026 07:30AM
Aug 13, 2026 07:30AM
Jul 14, 2026 06:55AM
May 26, 2026 07:15AM NervGen reports positive biomechanical gait analysis data for NVG-291
May 26, 2026 07:15AM
May 21, 2026 11:27PM
May 21, 2026 11:27PM
May 21, 2026 04:01PM
May 21, 2026 04:01PM
May 18, 2026 07:15AM
Apr 27, 2026 07:30AM NervGen names Keith Vendola as chief financial officer
Apr 27, 2026 07:30AM
Apr 13, 2026 07:45AM
Apr 13, 2026 07:45AM
Apr 7, 2026 12:26PM
Apr 7, 2026 07:30AM
Apr 7, 2026 07:30AM
Apr 7, 2026 07:30AM NervGen Pharma Announces Successful End-of-Phase 2 Meeting and FDA Alignment on RESTORE, a Phase 3 Registrational Study of NVG-291 for Chronic Tetraplegia
Mar 31, 2026 07:45AM
Mar 12, 2026 04:15PM
Mar 12, 2026 04:15PM
Mar 4, 2026 07:31AM
Mar 4, 2026 07:30AM
Feb 18, 2026 07:30AM
Feb 12, 2026 04:15PM NervGen Pharma CFO Bill Adams to retire in March
Feb 12, 2026 04:15PM
Feb 11, 2026 07:00AM
Feb 9, 2026 07:00AM
Feb 9, 2026 07:00AM
Jan 20, 2026 07:00AM
Jan 8, 2026 06:30AM
Mar 25, 2025 08:30AM NervGen Pharma to Host Virtual Investor Event
Jul 28, 2022 10:38AM
Jan 10, 2022 07:30AM
Jul 9, 2019 10:52AM
Jun 10, 2019 07:00AM
Jan 6, 2017 04:05PM

334,267 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All